MedTrace Logo

MACCE After Endoscopic Vein Harvest for CABG

NCT02471456 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2017-06-21

No results posted yet for this study

Summary

Most patients undergoing coronary artery bypass grafting (CABG) will require long saphenous vein (LSV) harvesting from the leg. This has been reported to be associated with a significant morbidity (leg swelling, pain, infection, bruising, wound discharge) in up to 50% of patients. Endoscopic vein harvesting (EVH) which has been reported to be associated with a reduction in these complications was implemented within the investigators' service in 2012. Although some initial reports of concerns regarding graft patency when the LSV is harvested by EVH, NICE and European Cardiology Society (ESC/EACTS) guidelines 2014 supported the use of the EVH technology. Last year a service evaluation in the investigators' department showed significant cost benefit of EVH as compared to open vein harvest (OVH) in a matched group (50 EVH and 50 OVH patients). The purpose of this study is to evaluate this group further to assess the incidence of MACCE (Major adverse cardiac and cerebrovascular event) and patient's quality of life (QOL) at least 1 year after their surgery. MACCE will be assessed by contacting the patient's GP and/or Cardiologist and QOL questionnaire (SF12v2) will be sent to patients along with a patient information sheet. It is estimated that data collection would be completed within 3 months of start.

Conditions

  • Complications Due to Coronary Artery Bypass Graft

Interventions

OTHER

Quality of Life Questionnaire

Quality of Life Questionnaire will be completed at least 1 year after their surgery.

OTHER

MACCE review

MACCE will be assessed by contacting the patient's GP and/or Cardiologist at least 1 year after their surgery.

Sponsors & Collaborators

  • Maquet Cardiovascular

    collaborator INDUSTRY

  • The Royal Wolverhampton Hospitals NHS Trust

    lead OTHER_GOV

Principal Investigators

  • Heyman Luckraz · The Royal Wolverhampton NHS Trust

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2015-10-16
Completion
2015-10-16

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02471456 on ClinicalTrials.gov